These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20383503)

  • 21. Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization.
    Kobbe G; Germing U; Soehngen D; Aul C; Heyll A
    Oncol Rep; 1999; 6(5):1151-2. PubMed ID: 10425318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response evaluation and monitoring of multiple myeloma.
    Fernández de Larrea C; Delforge M; Davies F; Bladé J
    Expert Rev Hematol; 2014 Feb; 7(1):33-42. PubMed ID: 24483347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
    Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
    Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 25. [The multiple myeloma--current view and perspectives].
    Knop S
    Med Monatsschr Pharm; 2014 Mar; 37(3):84-92; quiz 93-4. PubMed ID: 24741848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
    Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of chemotherapy in the treatment of multiple myeloma.
    Bergsagel DE
    Baillieres Clin Haematol; 1995 Dec; 8(4):783-94. PubMed ID: 8845572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
    Yuan ZG; Dun XY; Li YH; Hou J
    J Hematol Oncol; 2009 Apr; 2():19. PubMed ID: 19400935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical recovery from multiple myeloma. A report on 3 cases].
    Golenkov AK; Zlatkina AR; Grishchenko AB; Nazarova IN
    Gematol Transfuziol; 1988 Aug; 33(8):51-3. PubMed ID: 3192059
    [No Abstract]   [Full Text] [Related]  

  • 30. Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
    Guo HF; Su HL; Mao JJ; Sun C; Wang J; Zhou X
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):776-8. PubMed ID: 20979938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting PADI2 could stop the progression of myeloma.
    Tanday S
    Lancet Oncol; 2016 Aug; 17(8):e325. PubMed ID: 27425813
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
    Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma.
    Qazilbash MH; Saliba RM; Aleman A; Lei X; Weber D; Carrasco A; Champlin RE; Giralt SA
    Leuk Lymphoma; 2006 Jul; 47(7):1360-4. PubMed ID: 16923569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
    Cohen OC; Counsell N; Rabin N; Popat R; Owen RG; Popova B; Schofield O; Clifton-Hadley L; Lyons-Lewis J; Rawstron A; Spence C; de Tute RM; Hughes D; Moore S; Smith P; Yong KL
    Br J Haematol; 2019 Jun; 185(5):948-951. PubMed ID: 30460696
    [No Abstract]   [Full Text] [Related]  

  • 35. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
    Montefusco V; Spina F; Patriarca F; Offidani M; Bruno B; Montanari M; Mussetti A; Sperotto A; Scortechini I; Dodero A; Fanin R; Valagussa P; Corradini P
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):424-8. PubMed ID: 23142330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 37. The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
    Harrison SJ; Quach H; Link E; Feng H; Dean J; Copeman M; Van De Velde H; Schwarer A; Baker B; Spencer A; Catalano J; Campbell P; Augustson B; Romeril K; Prince HM
    Am J Hematol; 2015 May; 90(5):E86-91. PubMed ID: 25651830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compare before deciding. Cytotoxic drugs for relapsed or refractory multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):258. PubMed ID: 25954789
    [No Abstract]   [Full Text] [Related]  

  • 40. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.